Key result
Insulin use was associated with an increased risk of new-onset atrial fibrillation (OR 1.58; 95% CI 1.37-1.82), whereas DPP-4 inhibitors were associated with a lower risk (OR 0.65; 95% CI 0.45-0.93).
Why the study?
Does the use of different classes of antihyperglycemic drugs affect the risk of new-onset atrial fibrillation in elderly patients with diabetes?
Population
9,790 elderly patients with diabetes from Taiwan.
Comparison
Different classes of antihyperglycemic drugs vs Nonusers of the respective antihyperglycemic drugs
Design
Case-control
Follow-up
long-term follow-up (2005 to 2012)
Authors
Loading...
These associations should not alter prescribing; leaves open causal effects of antidiabetic agents on new-onset AF.
Case-Control (n=9,790)
Does the use of different classes of antihyperglycemic drugs affect the risk of new-onset atrial fibrillation in elderly patients with diabetes?
Odds Ratio: 1.58 (95% CI 1.37–1.82)
In elderly diabetic patients, DPP-4 inhibitors may protect against new-onset atrial fibrillation, whereas insulin therapy is associated with an increased risk.
Chen et al. (2017) conducted a case-control in New-onset atrial fibrillation (n=9,790). Insulin and dipeptidyl peptidase 4 inhibitors vs. Nonusers was evaluated on New-onset atrial fibrillation (OR 1.58, 95% CI 1.37-1.82). Insulin use was associated with an increased risk of new-onset atrial fibrillation (OR 1.58; 95% CI 1.37-1.82), whereas DPP-4 inhibitors were associated with a lower risk (OR 0.65; 95% CI 0.45-0.93).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: